The need for a new classification of cholesterol lowering therapies

Click to increase image sizeClick to decrease image size

Transparency

Declaration of funding

The authors declare no conflict of interest and have received no payment in preparation of this manuscript.

Declaration of financial/other relationships

L.M. has disclosed that he has been on advisory boards and/or received lecture fees from Hungarian branches of Amgen, KRKA, Richter Gedeon, Sandoz, Sanofi and MSD. G.P. has disclosed that he has no significant relationships with or financial interests in any commercial companies related to this study or article. K.K.R. has disclosed that he has been on advisory boards and/or received lecture fees from Pfizer, BMS, Astra Zeneca, MSD, Kowa, Abbott, Roche, Regeneron, Sanofi, Amgen, Aegerion, Lilly, Novartis, Novo Nordisk, and Boehringer Ingelheim; and received unrestricted research grant support from Pfizer, Regeneron, Sanofi, and BMS.